Ignite Creation Date:
2024-05-06 @ 6:30 PM
Last Modification Date:
2024-10-26 @ 2:49 PM
Study NCT ID:
NCT05687266
Status:
RECRUITING
Last Update Posted:
2024-07-09
First Post:
2022-12-28
Brief Title:
Phase III Open-label First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-12-29
Start Date Type:
ACTUAL
Primary Completion Date:
2027-02-22
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-02-22
Completion Date Type:
ESTIMATED
First Submit Date:
2022-12-28
First Submit QC Date:
January 17 2023
Study First Post Date:
2023-01-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-09
Last Update Post Date:
2024-07-09
Last Update Post Date Type:
ACTUAL